Key result
MicroRNA profiles in pericardial fluid did not significantly differ according to cardiovascular disease etiology or heart failure stage, despite the detection of several known heart failure markers.
Cross-Sectional (n=51)
No
Pericardial fluid contains a rich profile of microRNAs, including known heart failure markers, but these profiles do not distinguish between different cardiovascular pathologies or heart failure stages.
Pericardial fluid microRNAs lack discriminatory value for CVD etiology or HF stage; leaves open their biomarker utility pending prospective validation.
AIMS: Multicellular organisms maintain vital functions through intercellular communication. Release of extracellular vesicles that carry signals to even distant target organs is one way of accomplishing this communication. MicroRNAs can also be secreted from the cells in exosomes and act as paracrine signalling molecules. In addition, microRNAs have been implicated in the pathogenesis of a large number of diseases, including cardiovascular diseases, and are considered as promising candidate biomarkers due to their relative stability and easy quantification from clinical samples. Pericardial fluid contains hormones secreted by the heart and is known to reflect the cardiac function. In this study, we sought to investigate whether pericardial fluid contains microRNAs and if so, whether they could be used to distinguish between different cardiovascular pathologies and disease stages. METHODS AND RESULTS: Pericardial fluid was collected from heart failure patients during open-heart surgery. MicroRNA profiles of altogether 51 patients were measured by quantitative real-time PCR (qPCR) using Exiqon human panels I and II. On the average, 256 microRNAs were detected per sample, and 70 microRNAs out of 742 profiled microRNAs were detected in every sample. The five most abundant microRNAs in pericardial fluid were miR-21-5p, miR-451a, miR-125b-5p, let-7b-5p and miR-16-5p. No specific signatures for cardiovascular pathologies or clinically assessed heart failure stages could be detected from the profiles and, overall, microRNA profiles of the samples were found to be very similar despite the heterogeneity in the study population. CONCLUSION: Measured microRNA profiles did not separate the samples according to the clinical features of the patients. However, several previously identified heart failure marker microRNAs were detected. The pericardial fluid microRNA profile appeared to be a result of an active and selective secretory process indicating that microRNAs may act as paracrine signalling factors by mediating the local crosstalk between cardiac cells.
No takes yet. Share an insight, caveat, or question.
Linna-Kuosmanen et al. (2015) conducted a cross-sectional in Heart Failure (n=51). MicroRNA profiling of pericardial fluid vs. Different cardiovascular disease etiologies and NYHA classes was evaluated on MicroRNA profiles distinguishing between different cardiovascular pathologies and disease stages. MicroRNA profiles in pericardial fluid did not significantly differ according to cardiovascular disease etiology or heart failure stage, despite the detection of several known heart failure markers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: